Compare Stocks

→ Move Your Money Before May 1 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.22 +5.2%	$1.56	$1.15 ▼ $8.70	$19.18M	1.29	87,380 shs	104,863 shs
AVRO AVROBIO	$1.21 +1.7%	$1.27	$0.57 ▼ $1.70	$54.28M	1.22	269,863 shs	204,967 shs
PRTO Proteon Therapeutics	$3.05 +8.2%	$19.37	$0.22 ▼ $3.94	$67.65M	0.6	1.11 million shs	263,460 shs
PRVL Prevail Therapeutics	$23.00	$23.01	$9.02 ▼ $23.35	$787.66M	1.59	955,800 shs	N/A
SRNE Sorrento Therapeutics	$0.01 -42.2%	$0.02	$0.00 ▼ $0.42	$7.55M	2.25	482,392 shs	54,423 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	-4.92%	-8.66%	-27.50%	-41.41%	-83.67%
AVRO AVROBIO	-0.42%	-4.44%	-5.95%	-12.87%	+33.15%
PRTO Proteon Therapeutics	+8.16%	+10.91%	-23.56%	+29.79%	-2.87%
PRVL Prevail Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SRNE Sorrento Therapeutics	0.00%	-28.57%	+122.22%	-33.33%	-93.98%

Move Your Money Before May 22 (Ad)

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	2.7251 of 5 stars	3.5	5.0	0.0	0.0	3.1	0.0	0.6
AVRO AVROBIO	1.3892 of 5 stars	3.0	4.0	0.0	0.0	0.0	1.7	0.6
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.00	Buy	$19.80	1,522.95% Upside
AVRO AVROBIO	2.00	Hold	$2.00	65.29% Upside
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest APTO, SRNE, AVRO, PRVL, and PRTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$5.00
3/27/2024	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
2/1/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $5.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AVRO AVROBIO	N/A	N/A	$0.29 per share	4.15	$2.13 per share	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	($0.06) per share	N/A
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	$4.85 per share	N/A
SRNE Sorrento Therapeutics	$62.84M	0.12	N/A	N/A	($0.05) per share	-0.27

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$7.72	N/A	N/A	N/A	N/A	-458.70%	-205.30%	5/13/2024 (Estimated)
AVRO AVROBIO	$12.16M	-$0.10	N/A	N/A	N/A	N/A	-74.86%	-65.11%	5/9/2024 (Estimated)
PRTO Proteon Therapeutics	-$20.73M	-$1.15	N/A	N/A	N/A	N/A	N/A	-118.68%	N/A
PRVL Prevail Therapeutics	-$63.19M	-$2.22	N/A	N/A	N/A	N/A	-55.57%	-48.14%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/13/2024 (Estimated)

Latest APTO, SRNE, AVRO, PRVL, and PRTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APTO Aptose Biosciences	-$1.48	-$1.44	+$0.04	-$1.44	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	0.78	0.78
AVRO AVROBIO	N/A	15.78	15.78
PRTO Proteon Therapeutics	N/A	5.98	5.98
PRVL Prevail Therapeutics	N/A	7.56	7.56
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
AVRO AVROBIO	62.63%
PRTO Proteon Therapeutics	23.03%
PRVL Prevail Therapeutics	86.80%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	9.53%
AVRO AVROBIO	9.20%
PRTO Proteon Therapeutics	45.70%
PRVL Prevail Therapeutics	57.20%
SRNE Sorrento Therapeutics	2.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	15.72 million	14.22 million	No Data
AVRO AVROBIO	13	44.86 million	40.73 million	Optionable
PRTO Proteon Therapeutics	17	22.18 million	N/A	Not Optionable
PRVL Prevail Therapeutics	66	34.25 million	N/A	Not Optionable
SRNE Sorrento Therapeutics	799	551.28 million	536.95 million	Optionable

APTO, SRNE, AVRO, PRVL, and PRTO Headlines

Source	Headline
	Sorrento Therapeutics Inc SRNE morningstar.com - April 26 at 6:22 AM
	Sorrento Therapeutics (NASDAQ:SRNE) Now Covered by StockNews.com americanbankingnews.com - April 21 at 2:14 AM
	Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks news.bloomberglaw.com - March 27 at 4:18 AM
	Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks news.bloomberglaw.com - March 27 at 4:18 AM
	Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1) news.bloomberglaw.com - March 12 at 6:20 PM
	Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case wsj.com - March 12 at 6:20 PM
	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. tmcnet.com - February 27 at 9:57 AM
	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. businesswire.com - February 27 at 7:30 AM
	Sorrento Therapeutics pharmaphorum.com - February 7 at 10:34 AM
	5 Sanders Cove, Sorrento WA 6020 domain.com.au - January 18 at 9:02 AM
	Sorrento Therapeutics, Inc. (0L85.L) finance.yahoo.com - January 9 at 10:46 AM
	Sorrento WA 6020 domain.com.au - December 29 at 3:42 PM
	Sorrento Therapeutics Inc SRNEQ morningstar.com - November 5 at 10:27 AM
	29 Normanby Road Sorrento VIC 3943 domain.com.au - October 15 at 5:35 PM
	Sorrento, Italy - Weather Forecasts \| Maps \| News - Yahoo Weather yahoo.com - October 14 at 3:34 PM
	151 Seacrest Drive Sorrento WA 6020 domain.com.au - October 10 at 9:09 PM
	Sorrento holiday apartment accommodation with beach/lake nearby, internet access, balcony/terrace and air con holidaylettings.co.uk - October 9 at 7:15 PM
	9 Sunset Strip Sorrento VIC 3943 domain.com.au - September 14 at 9:37 AM
	Court rules Virpax CEO Anthony Mack breached his agreement with Sorrento Therapeutics bizjournals.com - September 7 at 5:29 PM
	122 Campbell Street Sorrento QLD 4217 domain.com.au - August 21 at 3:59 PM
	Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid finance.yahoo.com - August 8 at 11:08 AM
	Cheap Flights from Glasgow to Sorrento skyscanner.net - August 3 at 1:31 PM
	Cheap Flights from Edinburgh to Sorrento skyscanner.net - July 29 at 11:29 PM
	Cheap Flights from Bucharest to Sorrento skyscanner.net - July 29 at 1:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptose Biosciences

NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

AVROBIO

NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Proteon Therapeutics

NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Prevail Therapeutics

NASDAQ:PRVL

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Sorrento Therapeutics

NASDAQ:SRNE

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial